Complete Predicted Three-Dimensional Structure of the Facilitator Transmembrane Protein and Hepatitis C Virus Receptor CD81: Conserved and Variable Structural Domains in the Tetraspanin Superfamily  by Seigneuret, Michel
Complete Predicted Three-Dimensional Structure of the Facilitator
Transmembrane Protein and Hepatitis C Virus Receptor CD81: Conserved
and Variable Structural Domains in the Tetraspanin Superfamily
Michel Seigneuret
Institut Cochin, INSERM U567, CNRS UMR 8104, Universite´ Paris V, De´partement de Biologie Cellulaire, 75014 Paris, France
ABSTRACT Tetraspanins are a superfamily of transmembrane proteins implicated in cellular development, motility, and
activation through their interactions with a large range of proteins and with speciﬁc membrane microdomains. The complete
three-dimensional structure of the tetraspanin CD81 has been predicted by molecular modeling and from the crystallographic
structure of the EC2 large extracellular domain. Periodicity of sequence conservation, homology modeling, secondary structure
prediction, and protein docking were used. The transmembrane domain appears organized as a four-stranded left-handed
coiled coil directly connecting to two helices of the EC2. A smaller extracellular loop EC1 contains a small largely hydrophobic
b-strand that packs in a conserved hydrophobic groove of the EC2. The palmitoylable intracellular N-terminal segment forms an
amphipathic membrane-parallel helix. Structural variability occurs mainly in an hypervariable subdomain of the EC2 and in
intracellular regions. Therefore, the variable interaction selectivity of tetraspanins originates both from sequence variability
within structurally conserved domains and from the occurrence of small structurally variable domains. In CD81 and other
tetraspanins, the numerous membrane-exposed aromatic residues are asymmetrically clustered and protrude on one side of
the transmembrane domain. This may represent a functional specialization of these two sides for interactions with cholesterol,
proteins, or membrane microdomains.
INTRODUCTION
Tetraspanins constitute a superfamily of transmembrane
glycoproteins that are involved in the regulation of cellular
development, proliferation, activation, and motility. The best
characterized members include CD81, CD9, CD53, CD82,
CD151, CD37, and CD63. Their role is mediated by their
ability to interact with other proteins such as integrins, core-
ceptor molecules, major histocompatibility complex anti-
gens, and cytoplasmic kinases. Current hypotheses view
tetraspanins as ‘‘molecular facilitators’’ that simultaneously
interact with and bring into close proximity speciﬁc proteins
(for reviews see Hemler (1) and Levy and Shoham (2)). This
leads to the formation of large membrane complexes that
may become associated with lipid rafts and other micro-
domains (3–5) and the cytoskeleton (4). These complexes
are involved in speciﬁc activation, transduction, or signaling
processes. Tetraspanins themselves undergo homologous
and heterologous associations, which may form the basis of a
tetraspanin web (6,7). Several tetraspanins are also involved
in binding of viruses (8–10). CD81 is among the most stud-
ied tetraspanin with implications in numerous cellular pro-
cesses, among which are B- and T-cell activation (2,11). It
also acts as a receptor for HCV (8).
Tetraspanins are characterized by four transmembrane
segments (TM1-4) linked by one short extracellular (EC1),
one short intracellular (IC), and one large extracellular
(EC2) stretch (12). Tetraspanins also possess a number of
conserved residues including a glycine and four to eight
cysteines located on the EC2 stretch. Also partially con-
served is the so-called tetraspanin signature located in the
TM2/IC/TM3 region. Distant members of the tetraspanin
family also exist, such as RDS/ROM or uroplakins (13,14)
that share the same arrangement and EC2-conserved residues
but lack the signature.
Elucidation of the three-dimensional (3D) structure of
tetraspanins is essential to the understanding of their func-
tion. Some important progress has been made recently con-
cerning the large extracellular EC2 region that bears an
important part of the interaction capability of tetraspanins
(12). Kitadokoro et al. (15) reported the crystallographic
structure of a soluble form of the tetraspanin CD81 EC2
domain. The structure appears mushroom shaped and con-
sists of a ﬁve-helix bundle stabilized by two disulﬁde bridges
involving a ubiquitous CCG motif and other conserved cys-
teines. Seigneuret et al. (16) have used molecular modeling
to predict the structure of the EC2 over the whole super-
family. The structural features of the CD81 EC2 are con-
served only partially among tetraspanins. The EC2 is organized
in two subdomains. The ﬁrst, membrane proximal, sub-
domain has a structurally conserved fold among tetraspanins,
involving three helices (helices A, B, and E). The second
subdomain is sequentially inserted within the conserved
subdomain and located on its top. It is extremely variable in
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size and secondary structure among tetraspanins. The oc-
currence of two or more key disulﬁde bridges and other
invariant residues leads to a conserved relative topology of
both subdomains.
Although, the EC2 concentrates part of the interaction
potential of tetraspanins, numerous speciﬁc associations have
also been mapped in the transmembrane and intracellular
regions (2,12,17–20). Knowledge of the 3D structure of these
regions is therefore necessary to fully understand the
structure-activity relationships of tetraspanins. Recently Min
et al. (14) have used cryo-EM with a resolution of 7–10 A˚ to
visualize the uroplakin particle, a structure involving the
tetraspanin uroplakin 1a/b and another protein. In this work,
prediction of the complete structure of the tetraspanin CD81
has been attempted. Although the experimental cry-
stallographic structure has been used for the EC2, molecular
modeling has been used for the other regions.
EXPERIMENTAL PROCEDURES
General modeling procedures
All amino acid sequences were obtained from the SWISSPROT/TrEMBL
database. Protein coordinate ﬁle modiﬁcations and structural database
searches were done with Whatif (21). Homology modeling was performed
with the Modeller 6.2 program (22,23). Energy minimization of structures
was done with CHARMM (24). Packing quality in the modeled structures
was measured as residue packing values with the OS program (25). Interior
cavities were measured with Grasp (26). Residue accessibility was mea-
sured with Naccess (27). Structure quality was evaluated with Whatif and
Procheck (28). Protein structure visualization and representation were done
with Molmol (29).
Multiple sequence alignments and analyses
of transmembrane regions
An alignment of 204 tetraspanin sequences corresponding to 107 tetraspanin
types was generated with the ClustalX program (30) and improved
manually. Delimitation of the CD81 transmembrane regions were performed
using HMMTOP2 (31) and Perscan (32,33). Calculations of hydrophobic
and variability periodicity proﬁles and moments were done with Perscan.
For each transmembrane region or transmembrane/EC2 helix region, only
sequences of the alignment having .35% identity (25% for TM4) with
CD81 in the region were used.
Construction of the transmembrane coiled
coil template
To build the transmembrane domain of CD81, adequate coiled coil
templates were ﬁrst constructed. All available structures of transmembrane
proteins were searched for transmembrane coiled coil motifs using the
Socket program (34). A relatively regular fully antisymmetric left-handed
coiled coil arrangement of four transmembrane helices was found in cyto-
chrome oxidase subunit III (residues 128–256 of Protein Data Bank (PDB)
ﬁle 2OCC, chain C) (35). A quasiideal fully antisymmetric coiled coil was
built by covalently concatenating in a head-to-tail fashion identical copies of
the middle region of this four-helix domain (residues 135–142, 167–174,
205–212, 241–248), which is the most regular portion. Backbone stereo-
chemical imperfections were corrected and all side chains were then
transformed to alanine with Whatif. Because no semiantisymmetric left-
handed coiled coil was found in existing transmembrane protein structures,
a template corresponding to such fold was built from the fully antisymmetric
template by swapping two adjacent helices. Each of the two helices was ﬁrst
moved perpendicularly to the coiled coil axis and rotated along an axis par-
allel to the coil axis so that the a-carbons of its a core residues (respectively
its d core residues) were best ﬁtted to the initial position of those of the d core
residues (respectively the a core residues) of the other helix. Then the rota-
tional position of the two swapped helices were further adjusted visually so
that the positions of the a-carbons of their core residues were, mutually those
found for antisymmetric four-stranded left-handed coiled coils and, with
regard to the a-carbons of core residues of each other adjacent helix, those of
symmetric four-stranded left-handed coiled coils as in PDB ﬁle 1GCL (36).
Initial modeling and analysis of the CD81
transmembrane domain
Homology modeling of the six candidate folds of the CD81 transmem-
brane domain was performed using either the fully antiparallel or the semi-
antiparallel coiled coil templates. For each fold an alignment between the
sequence of the templates and the sequence of the CD81 transmembrane
domain (i.e., of trial transmembrane helical regions) was built so that the a,
d, e, and g positions of the coiled coil corresponded to those identiﬁed on
CD81 by sequence conservation analysis. Registering of the four helices was
unambiguous due to the necessity of having these regions at similar levels.
One-hundred structures were generated for each case using the model
routine of Modeller and 10 structures corresponding to the lowest values of
the Modeller objective function were selected and submitted to energy min-
imization using progressively decreasing harmonic restraints on backbone
atoms. Potential hydrogen bonds were detected interactively using the
SwisspdbViewer program (37) by trying all possible combinations of
rotamers of polar residue pairs located at suitable proximity.
Construction and positioning of EC1 domain
Secondary structure predictions of the EC1 were done with the Jnet method
(38) using multiple sequence alignments of each tetraspanin subfamilies.
A model of the b-strand region of the EC1, NLLYLE, was obtained by
searching theWhatif fragment database for similar segments. A segment with
the sequenceNLIYLA (residues 118–123 of PDBﬁle 1IS6), was transformed
to NLLYLE using the mutate function of Whatif. An ab initio NLLYLE
b-strand was also constructed with canonical dihedral angle values. Soft
docking of the EC1 b-strand on the CD81 EC2 crystallographic structure
(PDBﬁle 1G8Q (15))was performedwith both fragments using theGRAMM
program (39). High-resolution docking of the database b-strand fragment to
the EC2 was performed with the FTDOCK program (40). Docking solutions
were energy-ranked and ﬁltered to select those corresponding to the b-strand
position determined by soft docking and to its expected orientation. The ﬁve
best solutions were reﬁned with the MULTIDOCK program (41) and
analyzed for packing quality and steric clashes. The best model was slightly
reﬁned manually by adjusting dihedral angles to remove remaining clashes
and optimize packing and hydrogen bonding.
Complete modeling of the CD81 structure
The modeling of the CD81 complete structure was also performed by
homology. A full CD81 template was constructed by linking the fully
antisymmetric transmembrane coiled coil template to the docked EC1-EC2
complex with helical continuity between respectively TM3 and helix A of
the EC2 and TM4 and helix E of the EC2. The ﬁrst stage of modeling was
performed using the model routine of Modeller with the EC2 constrained to
its crystallographic conformation. Hydrogen bonds between transmembrane
helices were enforced by imposing conformational and interesidue distance
restraints. The best structure was selected from 500 simulations on three
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criteria: 1), low value of the convergence function; 2), compliance with
imposed restraints; 3), minimum steric clashes and packing voids. Reﬁne-
ment of loops was done simultaneously for EC1 loops (residues 39–42 and
49–55) and separately for the IC loop (residues 84–87) with the loop
Modeller routine. In both cases, a structure with low convergence function
and corresponding to the majoritary conformation for each loop was selected
from 100 simulations. The N-terminal regions was manually given a helical
conformation perpendicular to the transmembrane axis such that cysteine
and hydrophobic side chains face toward the extracellular side and polar side
chain toward the intracellular side. The C-terminal region was given a
relatively extended conformation also with such side-chain orientation. The
structure was then submitted to gentle energy minimization with ﬁxed
constraints on hydrogen-bonded side chains and progressively decreasing
residual harmonic constraints on all other atoms. The ﬁnal coordinate ﬁle has
been deposited at the PDB (entry 2AVZ). Stereochemical imperfections and
steric clashes are very limited (see the header of the PDB ﬁle for details).
Packing quality is such that six residues over 236 have a low packing score
as measured with Whatif and two packing voids with 41 and 48 A˚3 internal
volumes are found.
RESULTS
Identiﬁcation of transmembrane helical regions
The ﬁrst task of the modeling procedure of the transmem-
brane domain of human CD81 was to identify the limits of
the four transmembrane helices in the sequence. Complete
spanning of the lipid bilayer (;40 A˚) by a transmembrane
helix requires an at least 26-residue length (42). The results
obtained on CD81 with HMMTOP2 (30), which has recently
been evaluated as one of the most efﬁcient transmembrane
segment determination methods (43,44) are shown in Fig. 1
A. A model-independent method was also used, which is
valid for both transmembrane and water-exposed helices and
is based on the detection of regions with helical periodicity
of residue variability in a multiple sequence alignment
(32,33). Both methods yielded relatively similar limits for
transmembrane helices, which ranged between 24 and 27
residues. The results of the second method also indicate that
for TM3 and TM4, the periodicity extends beyond trans-
membrane regions to the EC2. This suggests that trans-
membrane helices in CD81 completely span the bilayer and
that TM3 and TM4 extend signiﬁcantly to the extracellular
aqueous phase (see below). To model the transmembrane
domain of CD81, it was therefore decided to ﬁrst assign trial
‘‘transmembrane helical regions’’, i.e., the portions of the
helices that span the bilayer, leaving the exact determination
of the helix ends to later modeling stages. Each 26-residue
transmembrane span was positioned taking into account
the results of the two prediction methods. This corresponds
to positions that are in between polar or charged residues
located in the nearby aqueous regions (Fig. 1 A).
Identiﬁcation of transmembrane bundle type and
interior residues
In the transmembrane domain of membrane proteins, ex-
terior residue facing the bilayer are on the average more
variable and hydrophobic than residues located in the protein
interior (32,33,45–47). This gives rise to a characteristic
periodicity of conservation and hydrophobicity along the
sequence that can be used to determine the helical pitch and
to identify the interior helix side. Because tetraspanins
constitute a superfamily, there are two types of conserved or
homologous residue sequence positions (homologous means
that the corresponding sequence position is occupied by
residues of the same chemical type): 1), positions that are
conserved or homologous for the whole superfamily; 2),
positions that are always conserved or homologous within
sequences of each tetraspanin type but different from one
type to the other. In an ensemble of 204 tetraspanin se-
quences, transmembrane segments could be unambiguously
aligned but a signiﬁcant sequence heterogeneity was found.
Respectively, 105, 125, 118, and 52 sequences had .30%
local identity with human CD81 for TM1-4, respectively.
Fig. 2 shows the mapping on helical wheels of residue
conservation for the four transmembrane helical regions of
CD81 together with the calculated hydrophobic and con-
servation moments. Two values of helical pitch were con-
sidered: 3.6 (Fig. 2 A) and 3.5 (Fig. 2 B) residues per turn.
This corresponds, respectively, to canonical straight
a-helices and left-handed coiled coils. Examination of the
latter case was suggested by numerous recent evidences of
a left-handed coiled coil organization of adjacent trans-
membrane helices in the structures of membrane proteins
(34,48–52). The packing of coiled coils involves speciﬁc
core residue positions termed a and d for the more internal
and e and g for the more external with repetitive spacing in
the sequences (heptad repeats) (53,54). Fig. 2 shows that
both helix models yield a clear periodicity of conservation: in
both cases conserved and homologous residues are mainly
segregated in one sector of each helix, which corresponds to
the direction of the conservation moment and is opposite to
that of the hydrophobic moment. This conﬁrms that the
transmembrane domain of CD81 indeed consists of four
helices that are organized as an approximately square bundle.
Helix interfaces correspond to the more conserved and
hydrophilic sectors. In agreement with the observation of Liu
et al. (52), the hydrophobic moment appears as a faithful
reporter of the lipid-exposed helix sides, when calculated
over a superfamily. Fig. 2 also indicates that for each helix,
the coiled-coil model yields a more clearcut segregation of
conserved and homologous residues in a narrower helix
sector. Furthermore, for this model, there are two adjacent
periodicity positions in which the most conserved residues
are concentrated and that correspond to the direction of the
conservation moment and are opposite to that of the hydro-
phobic moment. This is what is expected for the a and d core
residue positions of a transmembrane left-handed coiled coil.
This strongly suggests that CD81 transmembrane helical
regions are organized as a bundle that corresponds or at least
is close to that of a four-stranded left-handed coiled coil.
Another argument is presented in Fig. 2 C. Helix interactions
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in soluble (53,54) or transmembrane (34,48,52,55) coiled
coils are known to occur as knobs into hole interactions
between side chains of residues located at helix positions
a/d and e/g. The importance of residue side-chain volume
conservation among homologous proteins in such packing
has been emphasized (51–53). Fig. 2 C displays the helical
wheel representation of side-chain volume conservation for
a left-handed coiled coil. Helix positions in which small and
bulky residues are conserved are indicated. The helical
positions with conserved size are mainly the same, which are
suggested above on the basis of residue type conservation to
be the a/d and e/g positions of the proposed CD81 trans-
membrane coiled coil. There is a deﬁnite size conservation of
small residues (mainly glycine and alanine) at positions a and
d. The importance of such residues in promoting tight
packing of transmembrane coiled coil helices has previously
been emphasized (51,52,55,56). Such size conservation of
speciﬁc core residues in transmembrane helix sequences is
a further argument in favor of a four-stranded left-handed
coiled coil model for the organization of the CD81 trans-
membrane domain. Fig. 1 B shows the pattern of core residue
size conservation for representative sequences. Signiﬁcantly,
the so-called ‘‘tetraspanin signature’’, for nine of its 13
positions, actually correspond to a size-conservation pattern
of core residues in TM2 and TM3. Tetraspanin sequences
with local identity in each transmembrane region lower than
FIGURE 1 Secondary structure and size conservation in the transmembrane regions of CD81. (A) Location of transmembrane helical regions and other
regular secondary structure in the human CD81 sequence (H, helix; E, extended). (First row) Human CD81 sequence, positions corresponding to highly
(.90%) or signiﬁcantly (.75%) conserved residues of tetraspanin are, respectively, highlighted in black and gray; arrows indicate polar or charged residues
lining the transmembrane regions. (Second row) Transmembrane helical regions obtained using HMMTOP2. (Third row) Transmembrane helical regions
obtained with Perscan with an alignment of 41 tetraspanin sequences having.35% identity with CD81 in the transmembrane domain. (Fourth row) Starting
trial 26-residue transmembrane helical regions used for the modeling study. (Fifth row) Final secondary structure of CD81 obtained from molecular modeling
and the EC2 crystallographic structure. (B) Size conservation at the coiled coil core residue positions of the transmembrane helical regions of tetraspanins.
Small residues (G, A, S, T, C) are highlighted in black and bulky residues (I, LM, V, W, Y, F, E, Q, N, K, R) are highlighted in gray. Only core residues (a, d, e,
g) have been shaded for clarity. (First row) Assignment of coiled coil positions. (Last row) Size-conserved positions (s, small; b, bulky). Twelve
transmembrane residues belonging to the tetraspanin signature are indicated by asterisks.
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;30% were found to deviate locally from such conservation
properties. This may arise from correlated mutations (57) in
the superfamily in which concerted residue volume varia-
tions occur.
Relative topography of the transmembrane and
EC2 domains
In CD81, two helices of the transmembrane domain, namely
TM3 and TM4 are sequentially adjacent to two helices of the
EC2 domain, respectively, helices A and E (15), which are
roughly parallel in the EC2 structure. This raises the question
of whether there is a continuity of the helical conformation or
a nonregular loop conformation between the transmembrane
and EC2 helices. A strong indication of helical continuity
comes from the examination of the helical periodicity of
hydrophobicity and conservation in this region. Such an
approach has already been performed in photosynthetic
reaction centers (58). Both soluble and transmembrane sur-
face helices are expected to display a sequence periodicity of
conservation and hydrophobicity. If a transmembrane and
a soluble helix are separated by a nonordered region, a drop
of both periodicities in the sequence is expected. If there is
a continuous helix, when it emerges from the bilayer, con-
served residues remain on the same side toward the protein
interior whereas the more hydrophobic side in contact with
FIGURE 2 Helical wheel representation of residue types and size conservation in CD81 transmembrane regions. (A) Representation of residue type
conservation using a 3.6 residue-per-turn helical pitch (a-helix). The conservation of the residue position is indicated by the inner color of the circles in a linear
red to blue scale with blue meaning 100% conserved. Residue positions that are conserved or homologous in all sequences are, respectively, circled in black
and light blue. Residues positions that are variable among all sequences but conserved or homologous in all groups of sequences corresponding to a single
tetraspanin species are, respectively, circled in dark and light green. The threshold for residue conservation or homology is 90%. Considered homologous
residue families are: positive (H, K, R), negative-amidated (D, E, N, Q), hydroxylated (S, T), and aromatic (F, Y, W). The calculated conservation and
hydrophobic moments are indicated as blue and gray arrows, respectively. (B) Same as panel A but using a 3.5 residue-per-turn helical pitch (coiled coil). (C)
Representation of residue size conservation using a 3.5 residue-per-turn helical pitch (coiled coil). Residue positions that are conservatively occupied by a bulky
(I, L M, V, W, Y, F, E, Q, N, K, R) and a small (G, A, S, T, C) side chain are, respectively, ﬁlled in magenta and orange. The threshold for size conservation is
95%. For calculation of conservation properties of TM1-4, local alignments of 81, 81, 88, and 64 sequences having 35, 35, 35, and 25% local identity with
human CD81 were, respectively, used for each TM region. All helices are viewed from the intracellular side and the helix rotation sense is indicated by the
curved arrow. For coiled coils (3.5 residues per turn) the canonical residue positions a–d are indicated.
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lipids is continued by a more hydrophilic side in contact with
the aqueous phase (Fig. 3 A). One therefore expects a con-
tinuous conservation periodicity proﬁle and a drop of hy-
drophobicity periodicity proﬁle. As shown in Fig. 3 B, this is
the latter situation that is observed both in the TM3-helix A,
and helix E-TM4 regions. This strongly suggests the presence
of continuous helices between the transmembrane domain
and the EC2.
Arrangement of helices in the CD81
transmembrane bundle
The above results suggest that the transmembrane domain of
CD81 can be modeled as a square four-stranded left-handed
coiled coil. There are six possible such square arrangements
corresponding to six permutations of the four transmembrane
helices and therefore to six conﬁgurations of the soluble
segments IC, EC1, and EC2 (Fig. 4 A). These constitute three
pairs of pseudomirror images. The ﬁrst pair (1a and 1b)
corresponds to a fully antiparallel left-handed coiled coil
(i.e., all adjacent helices are antiparallel) whereas the two
others (2a/b and 3a/b) correspond to a semiantiparallel left-
handed coiled coil (i.e., two sets of adjacent helices are par-
allel and two sets are antiparallel).
To discriminate between the different folds, CD81 trans-
membrane domain structures corresponding to each fold
were modeled by homology, using fully antiparallel or
semiantiparallel transmembrane left-handed coiled coil tem-
plates (see ‘‘Experimental Procedures’’). A ﬁrst criteria to
select the correct fold was to investigate the possibilities of
direct connectivity between transmembrane and EC2 helices.
This made it possible to eliminate readily transmembrane folds
3a and 3b. Indeed, in these two folds TM3 and TM4 helices
are not adjacent. The measured minimum distance between
helix axes of TM3 and TM4 in the modeled 3a and 3b folds
is 13.8 A˚. On the other hand, in the EC2, helices A and E are
in contact and have a 10.2-A˚ interaxis distance. It is therefore
not possible to connect the EC2 helices to TM3 and TM4 in
the framework of transmembrane folds 3a and 3b.
In all four other folds, helices TM3 and TM4 are adjacent
and in close contact. The relative position of TM3 and TM4
is similar in folds 1a and 2a, as in folds 1b and 2b. A more
detailed analysis of the connectivity with the EC2 can be
used to discriminate between these two positions. Fig. 4 B
compares the connectivity of the EC2 helices A and E with
TM3 and TM4 in the framework of folds 1a and 1b. In fold
1a, the TM3 and TM4 interface mainly involves the a core
residues with more distant d residues, whereas the opposite
occurs in fold 1b. With fold 1a, TM3 and TM4 can be readily
connected to helices A and E of EC2 while matching both the
assignment of core a and d residues and the interhelix residue
distance (the distance between the a-carbons of N115 and
F198 is, respectively, 10.8 and 11.4 A˚ in the EC2 and in the
transmembrane fold 1a). On the other hand, there is no
connectivity between TM3, TM4, and the EC2 and the coiled
coil corresponding to conﬁguration 1b that satisﬁes at the
same time distance criteria between connecting residues (the
N115-F198 distance is 8.6 A˚), the assignment of core a and
d residues, and a continuous helical conformation. A similar
argument can be used to discard fold 2b. The existence of
transmembrane coiled coil folds (1a and 2a), which can be
FIGURE 3 Characterization of the continuity between transmembrane
and EC2 helices. (A) Principle of the method (58). A transmembrane bundle
is depicted in which a transmembrane helix in continuity with a soluble helix
is highlighted. The helix is in contact with the protein interior and the
external medium in both environments. When the helix emerges from the
bilayer, conserved (nonhatched) and variable (hatched) residues, respec-
tively, remain on the interior and exterior side of the helix whereas the more
hydrophobic residues (dark gray) and the more hydrophilic (light gray)
switch to opposite sides. This yields a continuous conservation periodicity
proﬁle and a drop of hydrophobicity periodicity proﬁle. (B) Variation in the
index of the helical (3.6 residue-per-turn) periodicity for sequence
conservation (solid line) and sequence hydrophobicity (dotted line). (Top)
Region connecting TM3 to EC2 helix A. (Bottom) Region connecting EC2
helix E to TM4. The periodicity analysis was done with the Perscan software
with alignments of, respectively, 47 and 39 sequences with .35%
homology with CD81 in the corresponding regions. The horizontal dotted
line corresponds to the limit of signiﬁcant periodicity. Identical results were
obtained when a pitch of 3.5 residue-per-turn was used.
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connected to the EC2 domain with a helical continuity and
a consistent succession of helical residues is a further argu-
ment in favor of such continuity.
The two remaining transmembrane folds 1a and 2a have
identical positioning of TM3 and TM4 and swapped
positioning of TM1 and TM2. These, respectively, corre-
spond to a fully antiparallel and a semiantiparallel left-
handed coiled coil. The second arrangement is a priori less
probable because it is not found among natural or artiﬁcial
soluble four-stranded coiled coils nor in transmembrane
proteins. Furthermore, in transmembrane proteins, sequen-
tially adjacent helices usually directly interact (59), which is
the case in fold 1a but not in fold 2a. To further discriminate
between these two folds, helix-helix interactions were
examined. Stability of transmembrane helical bundles
mainly results from: 1), surface complementarity between
adjacent helices resulting in close packing and efﬁcient Van
der Waals interactions; and 2), hydrogen bonding between
polar residues located at helix-helix interfaces (60–62). Helix
packing in the modeled CD81 transmembrane domains
corresponding to the two folds was examined by calculating
the packing values (25,52) of helix interior residues a, d, e,
and g, as well as the volume of internal cavities, represen-
tative of packing defects. As shown in Table 1, there is a
signiﬁcantly better packing in the fully antiparallel fold 1a.
This is more marked for TM1 and TM2, which are swapped
in the two folds. This is due to a better size complementarity
of interior core residues in fold 1a than in fold 1b. There are
several small size-conserved residues in TM2 that interact
with also mostly size-conserved very bulky residues of TM1
in fold 1a (see below). In fold 2a, TM1 and TM2 are in
contact on the opposite sides of their interior surfaces so that
this size complementarity is mostly lost. Both models were
also evaluated with regards to hydrogen bonding of interior
residues of adjacent helices. There are ﬁve interior hydrogen-
bonding side chains, namely N18 and W22 in TM1, E105 in
TM3, as well as E219 and S223 in TM4 (glutamic acids are
expected to be protonated). As indicated in Table 1, fold 1a
affords the formation of two hydrogen bonds between side
chains of adjacent helices, namely N18-S223 and W22-
E219. Oppositely, no side-chain/side-chain hydrogen bonds
are possible with fold 1b due to the fact that TM1 and TM4
are not adjacent. In none of the two folds is a side chain
available for hydrogen bonding with E105 of TM3. However,
in membrane protein structures, 50% of interior glutamic
acid side-chain hydrogen-bond with backbone atoms of ad-
jacent helices (62). Here, it was indeed possible to form a
TABLE 1 Helix-helix interactions in CD81 transmembrane
folding models
Fully
antiparallel (1a)
Semi
antiparallel (1b)
TM1 0.477 6 0.009 0.421 6 0.012
Average packing value
of core residues
TM2 0.463 6 0.010 0.420 6 0.013
TM3 0.449 6 0.009 0.431 6 0.011
TM4 0.498 6 0.010 0.475 6 0.009
Total internal cavity
volume (A˚3)
145 6 56 293 6 67
Potential interhelix
side-chain H-bonds
2 0
Packing values are averages for each transmembrane helix of values
measured for a, d, e, and d type residues and on 10 distinct homology
modeling simulations. Internal cavity volumes are averages on 10 distinct
homology modeling simulations.
FIGURE 4 Possible folds of a square four-helix bundle and discrimination
between folds 1a and1b. (A) The six possible folds obtained bypermutation of
helices. (B) Backbone representation of the EC2 and its connectivity with
the modeled transmembrane domain for folds 1a (left) and 1b (right).
Transmembrane helices TM3 and TM4 and EC2 helices A and E are drawn in
dark gray and thicker bonds. The Ca atoms of the internal coiled coil core
residues a and d are, respectively, represented in light gray and black and
labeled.
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hydrogen-bond between the protonated carboxyl of E105
and the peptide carbonyl of A209 of TM2 (in both folds
because the TM3-TM4 relation is the same). Interestingly,
Liu et al. (52) recently reported that alanine carbonyls
constitute a preferential site for interhelix hydrogen bonds of
aspartic acid and asparagine side chains. In both models,
TM2 has no interhelix hydrogen bond, being devoid of
suitable interior residues. In all, these data indicate that fold
1a not only affords a better packing of the transmembrane
domain of CD81 but also a higher interhelix hydrogen
bonding potential. It is therefore likely that this is this fold
that is adopted by CD81.
Conformation and positioning of the EC1 domain
The ﬁrst extracellular segment EC1 of tetraspanins is vari-
able in size and sequence among tetraspanin species. The
secondary structure of the EC1 of CD81 and other tetra-
spanins was predicted by methods designed for soluble pro-
teins (38). Despite high sequence divergence, the EC1 of
most tetraspanins has a conserved secondary structure, namely
a small central b-strand (extended structure) ﬂanked by non-
regular structure stretches. Among 37 tetraspanin species
(corresponding to 110 sequences) for which this prediction
was carried out, 26 contained such a b-strand. This may
reﬂect the nontotal accuracy of the method (38) or a limited
structural heterogeneity among tetraspanins. The secondary
structure predictions of the EC1 of representative tetraspa-
nins are shown in the left side of the alignment of Fig. 5 A.
The length of the predicted EC1 b-strand is variable ranging
from three to seven residues. Again, this may represent an
actual variable length of the b-strand or an accuracy limi-
tation of the method.
As shown in Fig. 5 A, for all sequences, the EC1 b-strand
is enriched in hydrophobic residues. In CD81, it has the
sequence ELLYLQ. Considering the predicted continuity of
TM3 and TM4 with EC2 helices and the predicted relative
topology of TM1-4 in fold 1a, the EC1 is expected to be in
contact with a region made of residues belonging to helices
A, E, and B (15) of the conserved subdomain of the EC2
(16). The right side of the alignment in Fig. 5 A highlights
the polar and nonpolar EC2 residues corresponding to this
region in several tetraspanin sequences. In the CD81 EC2
structure this region forms a groove and its center corresponds
FIGURE 5 Characterization of the conformation of
the CD81 small extracellular domain EC1 and its
interaction with the large extracellular domain EC2. (A)
Sequence alignment of tetraspanins emphasizing the
conservation of secondary structure and residue polarity
in the EC1 region and in the conserved subdomain of the
EC2. The predicted regular secondary structure regions
of the EC1 as well as the experimental secondary
structure regions of the EC2 obtained by crystallography
for CD81 are indicated on top, respectively, in green and
red (E, extended; H, helix). The limits of the predicted
EC1 b-strand are boxed in green on each tetraspanin
sequence. Hydrophobic residues are in blue and polar
residues are in pink. EC2 residues involved in contact
with the EC1 are indicated by an asterisk. (B) Prediction
of EC1 b-strand/EC2 interactions. (Left) Identiﬁcation of
the EC1 b-strand interaction region on the EC2 by blind
soft docking. The EC1 b-strand is shown as backbone-
only bond representation and colored in green. The
molecular surface of the EC2 is colored to emphasize
hydrophobic (blue) and polar (pink) residues in the EC1
interaction region. Results of 30 simulations of docking
are shown. (Right) Final modeling of the EC1 b-strand/
EC2 interaction by high-resolution docking followed by
manual adjustment. EC1 side chains are shown. Two
modeled EC1-EC2 hydrogen bonds are indicated in red.
CD81 Tetraspanin Modeled 3D Structure 219
Biophysical Journal 90(1) 212–227
to a conserved hydrophobic surface (15,16). This raises the
possibility that in the CD81 structure, the EC1 b-strand
packs in this groove, mainly through hydrophobic contact.
To obtain a model-independent evaluation of this hypoth-
esis, ‘‘blind’’ docking simulations were performed. The EC1
b-strand was considered as a ligand and its interaction site
on the EC2 was predicted. A soft-docking approach was
used, which, at the expense of accuracy of the docked
complex, allows for uncertainties in the conformation of the
ligand and the target (39). The left side of Fig. 5 B shows the
result of such a simulation using a six-residue NLLYLE
strand that was modeled from a homologous strand region
obtained by structural database search (see ‘‘Experimental
Procedures’’). Similar results were obtained with a six-
residue strand modeled ab initio. Almost all docking results
aim to a location of the b-strand at the expected position.
Although this approach indicates that the considered EC2
region constitutes a preferential site for a six-residue
b-strand, its resolution is limited. However, once the
approximate position of the EC1 strand relative to the EC2
was delimited, it was possible to use a higher resolution
docking method (40,41) to predict the most likely arrange-
ment. As shown in the right side of Fig. 5 B, this method
indicates that the EC1 strand packs inside the EC2 groove
with its hydrophobic residues interacting with the hydro-
phobic surface. Two hydrogen bonds with the EC2 were
tentatively formed by slightly adjusting the conformation of
two side chains.
Conformation of the N- and C-terminal regions
The N- and C-terminal regions of CD81 are close to the
intracellular membrane surface. Secondary structure pre-
diction suggests a nonordered conformation for these seg-
ments. However, the N-terminal region contains cysteine
residues known to be palmitoylated in situ (12,63,64). When
this segment is placed on a helical wheel, hydrophobic
residues and palmitoylable cysteines are located on one side
of the helix and hydrophilic residues on the other side (not
shown). Such amphipathic helices are common in membrane
protein structures and adopt a membrane-parallel orientation
with hydrophobic and hydrophilic residues, respectively,
facing inward and outward (65). It is proposed that the
N-terminal segment once palmitoylated is structured at the
membrane interface and adopts such an amphipathic helix
conformation. The C-terminal region of CD81 probably
adopts a random conformation although hydrophobic and
hydrophilic side chains may on the average also orient,
respectively, toward and away from the membrane.
Complete molecular modeling and architecture
of the 3D CD81 structure
To obtain a complete 3D model of the CD81 structure, a
homology modeling procedure was used with a full template,
built by assembling a fully antiparallel transmembrane left-
handed coiled coil template with the predicted EC1 b-strand/
EC2 complex. Exact ends of transmembrane helices were
ﬁxed by trial and error. The IC end of TM1 was ﬁxed to
Y12 because a two-residue loop was necessary to orient
the C-terminal amphipathic helix perpendicularly to the
transmembrane domain. The IC ends of TM2 and TM3 were
ﬁxed to A83 and Q88. This is necessary to have the
palmitoylable C89 exposed to the bilayer. This also affords
similar level ends to the two helices and a four-residue IC
loop sufﬁcient for closure. The IC end of TM4 was ﬁxed to
C228 to end at a similar level relative to the bilayer as the
other helices. On the EC side, extending TM1 and TM2,
respectively, by two and three residues was necessary to
avoid packing voids in the EC1 region of the ﬁnal 3D
structure. This locates the EC ends of TM1 and TM2 next to
two proline residues. Prolines have been demonstrated to be
efﬁcient breakers at the end of transmembrane helices (66).
Finally, the N-terminal and C-terminal segments were,
respectively, given a helical and roughly extended confor-
mation orienting hydrophobic residues and cysteines toward
the transmembrane domain and hydrophilic residues toward
the IC side. The ﬁnal limits of the secondary structure of
CD81 are indicated in Fig. 1 A.
The resulting 3D structure of CD81 is shown in Fig. 6 A.
The structure is cylindrical and very compact. After emerg-
ing from the bilayer, TM3 and TM4 become helices A and E
of the EC2 and remain packed, although departing from their
coiled coil geometry due to the constraints of the EC2
tertiary structure. The EC1 packs against the conserved
subdomain of the EC2 mainly on helices A and E with its
b-strand running roughly antiparallel to helix B. Due to this
tight packing of the EC1 in the EC2 groove, the whole
extracellular domain more or less retains its mushroom
shape. It protrudes out of the bilayer by 33 A˚. The EC2
variable subdomain (16) is located on the side opposite to the
EC1 and forms one half of the mushroom head. In CD81, it
contains two small helices (C and D) (15). It is linked to the
conserved subdomain by two disulﬁde bridges. On the
intracellular side, the N-terminal amphipathic helix, the IC
loop, and the C-terminal disordered domain emerge in the
aqueous phase at similar levels, presumably interacting with
the membrane surface.
Fig. 6 B shows the distribution of polarity (67) on the
molecule. The transmembrane domain surface is remarkably
hydrophobic. Although moderately polar residues are often
found on the transmembrane surface of intrinsic proteins
(46), this is hardly the case for CD81 with only two
threonines, which are in a situation where they might
hydrogen bond. Positively or negatively charged residues are
only present in the region where the transmembrane domain
is expected to emerge in the extracellular aqueous phase.
There are no charged residues at intracellular transmembrane
helix ends, although several occur at the nearby aqueous
stretches. All these factors contribute to provide to CD81
220 Seigneuret
Biophysical Journal 90(1) 212–227
a relatively long hydrophobic portion of the transmembrane
domain (;35-A˚ length). Although the IC loop is highly
hydrophilic, the N-terminal membrane parallel helix and the
C-terminal disordered region are amphipathic (the hydro-
phobicity brought by palmitoylation of cysteine residues is
not represented in Fig. 6 B). The extracellular region is mainly
hydrophilic but is also characterized by the presence of
hydrophobic surface regions. Although the hydrophobic
patch initially found on the crystallographic structure of the
EC2 in the conserved subdomain (15,16) is now partially
hidden by the EC1, the region of the extracellular domain
located below helix E remains largely hydrophobic due to
the presence of four apolar residues in the EC1 strand.
The experimental data available to evaluate the modeled
CD81 structure consists ﬁrst of residues known to be access-
ible in CD81 and other tetraspanins. The structure was found
to be in agreement with this data (Table 2). CD81 contains
six palmitoylable cysteines (12,63,64) located in portions of
the protein close to the intracellular headgroup region of the
membrane. In the case of C6, C9, and C89, such accessibility
FIGURE 6 Architecture and polarity of the modeled CD81 3D structure. (A) Ribbon (left) and surface (right) representation of the CD81 tertiary structure
and topology. TM1-TM4, the conserved and variable subdomains of the EC2, the EC1, the IC loop, and the N-terminal and C-terminal regions are,
respectively, represented in marine blue, blue, royal blue, light blue, red, pink, green, yellow, magenta, and brown. Disulﬁde bridges are in yellow. (B) Surface
representation of residue polarity calculated according to Eisenberg et al. (67). The surface color range linearly from red to blue, corresponding, respectively, to
polar and hydrophobic. The expected limits of the lipid bilayer (40-A˚ thickness) and of the hydrophobic region (30-A˚ thickness) are indicated as thin gray lines.
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was explicitly used in the modeling procedure. C80, C227,
and C228 are found to be also accessible. Furthermore,
CD81 residues that correspond sequentially to palmitoylable
cysteines located at other positions in the tetraspanin CD151
(12) are also accessible. Unlike CD81, most tetraspanins are
also glycosylated. CD9 is expected to be glycosylated at two
asparagine side chains of the EC1 (68) that correspond to
EC1 residues largely solvent-accessible in the CD81 model.
Besides, in the CD81 modeled structure, no EC2 residue
known to be accessible is masked by the EC1. In particular,
CD81 residues involved in binding of the E2 glycoprotein of
HCV (12,15,69) remain accessible. This is also the case for
CD81 residues located in the structurally conserved sub-
domain of the EC2 and corresponding to N-glycosylated
positions in other tetraspanins (12,16) and for a residue that
corresponds to a cysteine involved in disulﬁde-mediated
dimer formation in RDS/peripherin (13).
Another type of data that can be used to evaluate the CD81
structural model is the cryo-EM work of Min et al. (14) on
the uroplakin particle. This evaluation is complicated by the
fact that the uroplakin particle building blocks are hetero-
dimers of the tetraspanin uroplakin 1a or 1b with the non-
tetraspanin single span transmembrane protein uroplakin 2 or
3. The current resolution does not allow one to distinguish
the two proteins. Each uroplakin particle heterodimer ap-
pears as a relatively cylindrical transmembrane structure
with a small (5-A˚ length) intracellular and a prominent (65-A˚
length) extracellular domain. According to the authors, the
long length of this extracellular domain is mainly due to the
nontetraspanin uroplakin 2 or 3. On the other hand, Min et al.
also show that the transmembrane zone of the heterodimer
can accommodate ﬁve transmembrane helices with four
forming a square bundle and the ﬁfth located on the side of
this square bundle. This is consistent with the modeling
work if one assumes that the square bundle corresponds to
the tetraspanin component of the heterodimer. Therefore, it
appears that the CD81 structural model is compatible with
the cryo-EM data.
Interactions between transmembrane helices in
the CD81 modeled structure
Two types of interactions are responsible for stabilizing the
transmembrane domain of CD81 and other tetraspanins,
namely Van der Waals interactions and hydrogen bonds.
Due to the accuracy limits of molecular modeling, only
a brief and qualitative description of these is given here.
First, there appears to be a size complementarity of many
small and bulky core residues in contact belonging to adja-
cent transmembrane helices. In all there are 26 proximities
between such residue pairs, more than half occurring
between size-conserved residues. In particular, near the
intracellular end of TM2, there is a cluster of small residues
belonging to the tetraspanin signature (G69, G76, G79, C80,
G82, and A83) that mainly interacts with another cluster of
very bulky residues of TM1 (Y12, F15, N18, F19, and W22)
in a size-complementary manner (not shown). Such ob-
servations suggest that size complementarity does indeed
play a role in the stability of the CD81 transmembrane do-
main. Fig. 7 shows the modeled (and therefore stereochemi-
cally approximative) network of hydrogen bonding between
transmembrane helices in CD81. There are two side-chain
hydrogen bonds between TM1 and TM4, namely N18-S223
and W22-E219. TM4 is also suggested to be connected with
TM3 through an H-bond between the side chain of E105 and
the backbone carbonyl of A209. On the other hand, TM2,
which is the less polar of all transmembrane helices, contains
no interior hydrogen bonding groups.
Topography of aromatic residues at the CD81
transmembrane domain surface
As found in transmembrane protein experimental structures
(42), the modeled CD81 structure possesses a number of
aromatic residues located on the surface of the membrane-
embedded domain (Fig. 8 A). Trp and Tyr side chains are on
the average more superﬁcial than Phe side chains, as is also
TABLE 2 Surface accessibility in the modeled CD81 structure
of tetraspanin residues involved in posttranslational
modiﬁcation and ligand binding
CD81
residue
Corresponding
residue in other
tetraspanin
Accessible
surface (A˚2)
Accessibility
criteria Reference
C6 – 52.2 Palmitoylation 12
C9 – 49.8 Palmitoylation 12
K52* N51 (CD9) 96.5 N-glycosylation 79
P53* N52 (CD9) 27.3 N-glycosylation 79
C80 – 23.0 Palmitoylation 12
Y81* C80 (CD151) 139.3 Palmitoylation 12
C89 – 102.5 Palmitoylation 12
D138* N129 (CD53, CD63) 106.0 N-glycosylation 16
N141* C151(peripherin) 97.8 Intermolecular
disulﬁde
13
L162 – 28.5 HCV glycoprotein
E2 binding
80
T163 – 79.5 HCV glycoprotein
E2 binding
15
I182 – 114.5 HCV glycoprotein
E2 binding
80
N184 – 17.6 HCV glycoprotein
E2 binding
80
F186 – 140.5 HCV glycoprotein
E2 binding
15
D196 – 50.8 HCV glycoprotein
E2 binding
15
M224* C242 (CD151) 88.2 Palmitoylation 12
V225* C243 (CD151) 64.0 Palmitoylation 12
C227 – 28.3 Palmitoylation 12
C228 – 74.7 Palmitoylation 12
In the ﬁrst column, residues without asterisks are known to be accessible in
CD81 whereas those with an asterisk are CD81 residues corresponding
sequentially to residues known to be accessible in other tetraspanins and
listed in the second column. Accessible surface includes side chain and Ca.
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observed experimentally (70). Considering the size of the
CD81 transmembrane domain, the number of such aromatic
residues is high, i.e., 16. This is mainly due to a high number
of Phe residues. Another uncommon property is that the
distribution and orientation of aromatic residues is non-
uniform. There are more aromatic residues (mainly Phe) in
one side of the transmembrane domain located toward TM1
and TM2. In addition, the aromatic residues on this side
appear to have a more protruding orientation (Fig. 8 A). This
latter property is due to differences in the coiled coil positions
occupied by the exposed aromatic residues in each TM helix
(b, c, and f positions have more protruding side chains than e
and g position). Despite a limited residue to residue conserva-
tion, the general trend of asymmetry of distribution of such
aromatic amino acids is conserved. Among 63 tetraspanin
species with transmembrane domains having more than 25%
sequence identity with that of CD81, 49 contain between 10
and 19 exposed transmembrane aromatic residues. Fig. 8 B
shows a mapping of the frequency of aromatic residues in
these sequences on the transmembrane surface of the CD81
structure. There is a deﬁnite accumulation of aromatic
residues on the side of the transmembrane domain located
toward TM1 and TM2. Tetraspanins that correspond to this
pattern include the most common members, CD9, CD53,
CD82, CD151, CD37, CD151 except for CD63.
DISCUSSION
In this work the complete structure of the tetraspanin CD81
has been modeled using various prediction and modeling
methods as well as the crystallographic structure of the EC2
domain. These results are consistent with current knowledge
of transmembrane protein structure. Furthermore, these pre-
dictions, although mostly derived independently from each
other, constitute a self-consistent ensemble. The accuracy of
the modeling is related to the current status of computational
methods. The best methods of transmembrane helix pre-
diction are in error on average by one helix turn at each end
(46). The secondary structure prediction method used to
predict the EC1 b-strand have an accuracy of only ;75%
(38). Also, here, the transmembrane domain of CD81 has
been modeled using a low computational cost homology
modeling procedure that has allowed to test the inﬂuence
of several parameters. Computationally intensive modeling
strategies of transmembrane domains exist that provide more
global searches of conformational space and have been
recently applied to transmembrane bundles with four dif-
ferent helices (47,71). Because the ﬁnal modeled CD81
structure has a suitable packing quality and is consistent with
experimental data, it appears to be a plausible working model
that might be improved in the future both experimentally and
computationally.
Some features of the CD81 structure suggest a new
interpretation of one aspect of the EC2 structural data. In the
EC2 crystal structure, a surface hydrophobic patch contrib-
uted by residues from helices A, B, and E is apparent and
corresponds to crystallographic contact between adjacent
EC2 molecules. This suggested that the hydrophobic patch
might be involved in tetraspanin interactions with them-
selves (15,16). Here, in the modeled CD81 structure, these
residues are in part masked by their interaction with the EC1.
This suggests that such masked residues are actually con-
served internal hydrophobic residues of the extracellular
domain that become unmasked in the soluble EC2. This is
consistent with the reports that the removal of the EC2 by
mutagenesis of CD151 does not affect its association with
itself and other tetraspanins (72) and that mutations of two
residues involved in the CD81 EC2 hydrophobic patch
(F150 and V146), although decreasing EC2 oligomerization
in solution, have no effect on CD81 homodimerization in situ
(73). Other structural factors are likely involved in tetraspanin-
tetraspanin interactions.
The availability of the CD81 modeled structure raises the
question of which aspects of the structure are common to all
tetraspanins. It seems likely that the arrangement of the
transmembrane domain as a four-stranded fully antisym-
metric left-handed coiled coil is common to most if not all
tetraspanins. This provides an explanation for the conserva-
tion of many small and bulky residues in the transmembrane
domain of tetraspanins (including the tetraspanin signature).
The situation is more complex with regard to the con-
servation of hydrogen bonding between transmembrane
helices. Only two of the transmembrane hydrogen bonding
residues of CD81 are highly conserved among tetraspanins,
namely N18 and E105 (occasionally replaced by Q). Most
FIGURE 7 Hydrogen bonds between transmembrane helices in the
modeled CD81 3D structure. The backbones of TM1, TM3, and TM4 are
drawn in bond representation and, respectively, colored in black, light gray,
and gray. Side chains and backbone involved in H-bonds are shown in ball-
and-stick and colored in dark gray except polar atoms that are drawn in light
gray. H-bonds are depicted as dotted lines.
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tetraspanins possess a hydroxylated residue corresponding
to S223 or at a nearby interior position of TM4 that may
provide hydrogen bonding to the conserved asparagine of
TM1. The position of A209 always corresponds to a small-
size residue, a feature that may facilitate hydrogen bonding
of the TM3 conserved glutamine to the backbone carbonyl.
On the other hand, most tetraspanins do not possess a polar
residue corresponding to E219 of CD81. Rather a conserved
E or Q residue is found in TM4 at a position corresponding to
interior residue M216 of CD81. A polar residue located at
such position would still be able to hydrogen bond to the
TM1 tryptophan corresponding to W22 (conserved in;50%
of tetraspanins). Alternatively, in other tetraspanins, unlike
for CD81, this TM4 E/Q residue would be at a suitable
distance to the E/Q of TM3 for H-bonding. Finally, in most
tetraspanins, TM2 is poor in hydrogen bonding residues.
This suggests that, whereas the exact interhelix hydrogen-
bonding network may be variable in tetraspanins, it mostly
involves TM1-TM4 and TM3-TM4 interaction. It seems also
likely that the continuity of EC2 helices with TM2 and TM3
is shared by most, if not all tetraspanins.
The majority of tetraspanins, including all well-character-
ized members, appears to possess a b-strand region in the
EC1. The b-strand is always enriched in hydrophobic resi-
dues, which interact with conserved hydrophobic residues of
the EC2 groove. In a previous study, it was found that,
despite limited sequence similarity, helices A, B, and E of
the EC2 form a structurally conserved subdomain among
tetraspanins (16). These data suggest that, for the majority of
tetraspanins, the EC1 shares a similar pattern, i.e., it has
a largely conserved structure despite signiﬁcant sequence
divergence. Because the conserved EC2 subdomain and the
EC1 are packed together, these appear to constitute a struc-
turally conserved extracellular subdomain. This conserved
subdomain is topped by a smaller structurally variable
subdomain (16). For CD81 and most tetraspanins, the region
of the conserved extracellular subdomain located below helix
B and opposite to the EC2 variable side is highly hydrophobic.
This is due to the occurrence of apolar residues in the EC1
b-strand as well as to conserved EC2 hydrophobic residues
not masked by the EC1. Therefore, this region constitutes a
potential site for protein-protein interactions.
Structural conservation on the intracellular side of
tetraspanin appears to be more contrasted. The small IC
loop connecting TM2 and TM3 is four-residue long in the
CD81 structural model. It corresponds to a sequence pattern
that is found in ;60% of tetraspanins and therefore likely
adopts a similar conformation. The N-terminal intracellular
FIGURE 8 Asymmetric distribution of exterior transmembrane domain
aromatic residues in CD81 and tetraspanins. (A) (Top) CPK representation of
the modeled CD81 structure highlighting exterior aromatic residues of the
transmembrane domain. Helices TM1-4 are colored as in Fig. 6 A except for
Phe, Tyr, and Trp residues, which are colored pink, magenta, and purple,
respectively. The rest of the molecule is in gray. Two opposite orientations
corresponding to the aromatic poor (left) and aromatic rich (right) sides are
shown. (Bottom) Bond representation of the CD81 transmembrane domain
viewed from the extracellular side. Only exterior aromatic side chains are
shown to illustrate their protruding or nonprotruding character. (B) Surface
representation of the modeled CD81 structure colored according to the
frequency of occurrence of transmembrane domain aromatic residues in
tetraspanins at the corresponding accessible residue position. Frequencies were
obtained from an alignment of 49 distinct tetraspanin species with both.25%
homology to CD81 in the transmembrane domain and.10 exterior aromatic
residues (one sequence per species). The surface color ranges linearly from
white to marine blue corresponding, respectively, to 0 and 0.77 (maximum
occurrence found) aromatic residue frequency. Orientations of the molecule
are identical to panel A.
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stretch of CD81, which contains two palmitoylable cys-
teines, has been modeled as a membrane-parallel amphi-
pathic helix; 40% of tetraspanin types contain a comparable
amphipathic pattern. Although many tetraspanins lack one
cysteine in this region, it is often replaced by a hydrophobic
residue so that the amphipathic character is retained. The
idea that this amphipathic helix is formed upon palmitoy-
lation suggests a possible mechanism for regulation of
tetraspanin interactions. Recently, the heterologous inter-
actions between tetraspanins have been shown to depend
upon palmitoylation (63). Interactions between the amphi-
pathic N-terminal helices may be involved in such inter-
actions. Finally, the intracellular C-terminal stretch is among
the most divergent region in tetraspanins. Although it is sug-
gested to be disordered in CD81, it may adopt speciﬁc con-
formations in other members, especially because it is often
involved in very speciﬁc functions (12).
The relatively long hydrophobic transmembrane region
found for CD81 may be signiﬁcant in view of the partial
association of tetraspanins with lipid rafts (3,4). In several
occasions (1,3), palmitoylation of tetraspanins was found to
have no effect on their raft location. Rafts are characterized
by a larger thickness of the hydrophobic bilayer portion and
the length of the transmembrane domain has been suggested
as a sorting criteria for intrinsic proteins (74). A possible role
of Trp and Tyr side chains located near the headgroup region
must also be considered because these may adapt to hydro-
phobic mismatches through transversal changes in their
position (75). It may be the combined properties of the hy-
drophobic region and of the aromatic belt that allow tetra-
spanins to reside both in raft and nonraft regions. A related
structural pattern that appears to be conserved, at least in
;50 tetraspanin species is constituted by clusters of pro-
truding aromatic residues asymmetrically located on one side
of the transmembrane domain. Such lateral asymmetry may
reﬂect a specialization of the two sides of the transmembrane
domain for distinct protein interactions, e.g., homologous or
heterologous tetraspanin interactions or interactions with
tetraspanins and with other partners. Alternatively, because
recent data by Charrin et al. (76) suggests a physical in-
teraction between cholesterol and tetraspanins, it is possible
that the transmembrane surface aromatic residues are in-
volved in one or several cholesterol-binding sites. Indeed,
recently proposed putative cholesterol sites of other proteins
seem to invariably involve aromatic residues (77–79). This
may be also signiﬁcant for tetraspanin-raft interaction. In a
more speculative manner, this lateral asymmetry of aromatic
residue distribution in the transmembrane domain of tetra-
spanin may also favor their location at the boundary of two
distinct types of membrane microdomains, e.g., raft and
nonraft. The idea that proteins with asymmetric lipid inter-
actions might stabilize lipid regions with differing compo-
sitions has been proposed (80).
One particularity of tetraspanin interactions is their vari-
ous levels of speciﬁcity. Several tetraspanins share identical
molecular partners (e.g., CD4, CD8, EWI-1, EWI-F) or
partners from the same type (e.g., integrins, MHCmolecules,
other tetraspanins). On the other hand, each tetraspanin also
has very speciﬁc partners (1,2,12,17–20). This work sug-
gests that the selectivity of tetraspanins originates from two
simultaneous properties: i), sequence variability within struc-
turally conserved domains; ii), occurrence of limited-size
structurally variable domains.
Note added in proof : Recently, Kovalenko et al. (81) reported the oc-
currence of heptad repeats in three transmembrane helices (TM1-3) of 28
tetraspanin sequences and emphasized the role of contacts between small
and bulky residues in TM1-TM2 interactions in the tetraspanin CD9.
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